Recent Updates
Recently added Catalysts

Arcellx, Inc.

ACLX
Richly ValuedBiotech · Clinical
FDA catalysts, PDUFA dates & pipeline intelligence
$115.07
▲ +0.03 · +0.03%

Last traded Apr 27, 2026. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full ACLX financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $47.8652W HIGH $115.13
Volume
16.12 M
Value Traded
1.85 B
Short % Float
4.31%
+0.01%Week
+0.39%1 Month
+68.26%3 Month
+31.98%6 Month
+505.63%5 Year
+505.63%All Time

Cash Data

Unlock ACLX cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
6.73 B
EPS (TTM)
-4.05
P/E Ratio
-
Ent. Value
6.33 B
Total Shares
58.46 M
Float Shares
41.80 M
Insiders
22.44%
Institutions
74.14%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA
2026
Example Drug
Treatment for example condition requiring FDA review
Phase 3Small MoleculeOncology-
Unlock every ACLX catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

ACLX Catalyst Timeline

Dated clinical, regulatory and corporate events for Arcellx, Inc.

Unlock the full ACLX catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How ACLX actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2024-12-09Anitocabtagene Autoleucel (anito-cel) Phase 2 data readout Phase 2
Unlock all ACLX historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

D31 / 100
Pipeline Score
$295M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Arcellx, Inc. faces pipeline headwinds (31/100), with $475M risk-adjusted pipeline value, led by anito-cel (anitocabtagene autoleucel) in Muscular Diseases (Phase 1).
Showing 1 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
anito-cel (anitocabtagene autoleucel) CAR-TNCT06626919Muscular DiseasesPhase 1 RECRUITING 30Apr 1, 2028
Unlock the ACLX pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every ACLX program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
anito-cel relapsed and/or refractory multiple myelomaPhase 22025-05-14ORR: 97%; CR/s CR: 68%; VGPR: 85%; MRD negativity: 93.3%; 6 month PFS: 91.9%; 6 month OS: 96.6%; 12 month PFS: 78.8%; 12 month OS: 95.2%Read MoreArcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma Results from all 117 patients dosed in the pivotal Phase 2 iMMagine-1 study of anito-cel demonstraRead More
Scroll for more · summaries link to the source press release
Unlock every ACLX trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock ACLX insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Carroll JillDirectorDisposition due to tender of shares -1,479,148 $0.00 04/28/2026
Unlock the full ACLX insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in ACLX

Fund % of Portfolio Current MV Shares Owned Activity
Paradigm Biocapital Advisors LP 13.5 % (42.1 %) 662.97 M 5.77 M 0.87% ( 50.00 K)
Unlock every fund holding ACLX
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in ACLX
Shares held by hedge funds each quarter, and who bought or sold.

ACLX Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock ACLX option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live ACLX option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock ACLX options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How ACLX ranks across every disease it competes in

Competitive Position is a premium feature
See how ACLX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

ACLX News

About Arcellx, Inc.

Redwood City, CA 209 employees arcellx.com
Headquarters800 BRIDGE PARKWAY, REDWOOD CITY, CA, 94065
Founded2014
BIOPHARMAWATCH ELITE PLUS
Trade the next ACLX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime